Seeking to expand the knowledge base surrounding spectral flow
cytometry, Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell
analysis solutions company, has launched a global roadshow called
Cytek Reveal. The roadshow will kick off in South San Francisco on
October 5, 2023, and will include stops in San Diego, Boston,
Toronto and Cambridge, United Kingdom. Each stop will feature four
distinct educational presentations that demonstrate how spectral
flow cytometry can be used across a range of applications for
analysis and sorting. Highlighted topics will include the
similarities and differences, along with backward compatibility,
between spectral and conventional cytometry. Spectral technology
enables flexibility and high-resolution power, spanning from
low-color to complex assays.
Recognized as a pioneer in spectral flow
cytometry, Cytek is the creator of the first commercialized
fluorescence-based flow cytometry platform to achieve 40 colors –
effectively shifting the paradigm of what scientists thought was
possible in flow cytometry. The company’s patented Full Spectrum
Profiling™ (FSP™) technology empowers scientists, allowing them to
go even further with their research – all with greater ease and
shorter time to results compared to conventional flow cytometry.
While the platform supports generation of high-resolution
multiparametric data, Cytek’s FSP™ technology has proven to be
useful across all flow cytometry applications.
The Cytek Reveal Roadshow will provide
participants with an insider’s look into the breakthroughs that are
possible using FSP™ technology. They will also learn about Cytek’s
extensive suite of solutions for the single cell analysis market
that streamline workflows, accelerate discoveries and maximize
efficiency – including the Cytek® Aurora CS system.
Sessions will be led by Dr. Maria Jaimes,
Cytek’s vice president of scientific commercialization. Dr. Jaimes
was part of the original team credited for developing and
commercializing Cytek’s Aurora full spectrum cytometer and is a
subject matter expert on multicolor flow cytometry.
“At Cytek, we’re committed to developing the
tools that will advance the next generation of cell analysis – and
becoming the partner of choice throughout the life sciences
community,” said Dr. Wenbin Jiang, CEO of Cytek Biosciences. “We
take the word ‘partner’ very seriously, and constantly adapt our
offerings to meet the needs of users. Our entire lineup is
user-friendly and intuitive, allowing scientists at all levels to
advance their research. We invite you to attend one of our
roadshows and join us in the spectral revolution.”
Cytek solutions are well established globally,
with over 1,300 peer-reviewed publications referencing the use of
Cytek solutions in research ranging from immuno-oncology to
infectious diseases and immunology. Backed by its hands-on,
exceptional technical applications support teams, Cytek products
are used at many of the world’s most renowned pharmaceutical
companies, CRO firms, and academic research institutions.
“The Cytek perspective centers on technology as
an enabler of scientific progress,” Dr. Jiang continued. “We are
dedicated to crafting tools that empower scientists, and seek to
foster accessibility and ease of use without compromising
capabilities. By simplifying complex technologies, we allow
researchers to channel their energy into what they do best –
exploration and discovery.”For more information and details on the
Cytek Reveal Roadshow, please visit www.cytekbio.com/reveal or
www.cytekbio.com.
About Cytek Biosciences,
Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading
cell analysis solutions company advancing the next generation of
cell analysis tools by delivering high-resolution, high-content and
high-sensitivity cell analysis utilizing its patented Full Spectrum
Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the
power of information within the entire spectrum of a fluorescent
signal to achieve a higher level of multiplexing with precision and
sensitivity. Cytek’s FSP platform includes its core instruments,
the Aurora and Northern Lights™ systems; its cell sorter, the
Aurora CS; the flow cytometer and imaging products under the Amnis®
and Guava® brands; and reagents, software and services to provide a
comprehensive and integrated suite of solutions for its customers.
Cytek is headquartered in Fremont, California with offices and
distribution channels across the globe. More information about the
company and its products is available at www.cytekbio.com.
Cytek’s products are for research use only and
not for use in diagnostic procedures (other than Cytek’s Northern
Lights-CLC system and certain reagents, which are available for
clinical use in China and the European Union).
Cytek, Full Spectrum Profiling, FSP, Northern
Lights, Amnis and Guava are trademarks of Cytek Biosciences,
Inc.
In addition to filings with the Securities and
Exchange Commission (SEC), press releases, public conference calls
and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn
page and X (formerly Twitter) account as channels of
distribution of information about its company, products, planned
financial and other announcements, attendance at upcoming investor
and industry conferences and other matters. Such information may be
deemed material information and Cytek may use these channels to
comply with its disclosure obligations under Regulation FD.
Therefore, investors should monitor Cytek’s website, LinkedIn page,
and X account in addition to following its SEC filings, news
releases, public conference calls and webcasts.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 as
contained in Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
which are subject to the “safe harbor” created by those sections.
All statements, other than statements of historical facts, may be
forward-looking statements. Forward-looking statements generally
can be identified by the use of forward-looking terminology such as
“may,” “might," "will,” “should,” “expect,” “plan,” “anticipate,”
“could,” “intend,” “target,” “project,” “contemplate,” “believe,”
“estimate,” “predict,” “potential” or “continue” or the negatives
of these terms or variations of them or similar terminology, but
the absence of these words does not mean that a statement is not
forward-looking. These forward-looking statements include
statements regarding Cytek’s product development goals and business
strategies. These statements are based on management’s current
expectations, forecasts, beliefs, assumptions and information
currently available to management. These statements also deal with
future events and involve known and unknown risks, uncertainties
and other factors that may cause actual results, performance or
achievements to be materially different from the information
expressed or implied by these forward-looking statements. Factors
that could cause actual results to differ materially include risks
and uncertainties such as those relating to global economic and
market conditions; Cytek’s dependence on certain sole and single
source suppliers; competition; market acceptance of Cytek’s current
and potential products; Cytek’s ability to manage the growth and
complexity of its organization, maintain relationships with
customers and suppliers and retain key employees; Cytek’s ability
to maintain, protect and enhance its intellectual property; and
Cytek’s ability to continue to stay in compliance with its material
contractual obligations, applicable laws and regulations. You
should refer to the section entitled “Risk Factors” set forth in
Cytek’s Quarterly Report on Form 10-Q filed with the SEC on August
8, 2023 and other filings Cytek Biosciences makes with the SEC from
time to time for a discussion of important factors that may cause
actual results to differ materially from those expressed or implied
by Cytek’s forward-looking statements. Although Cytek believes that
the expectations reflected in the forward-looking statements are
reasonable, it cannot provide any assurance that these expectations
will prove to be correct nor can it guarantee that the future
results, levels of activity, performance and events and
circumstances reflected in the forward-looking statements will be
achieved or occur. The forward-looking statements in this press
release are based on information available to Cytek as of the date
hereof, and Cytek disclaims any obligation to update any
forward-looking statements provided to reflect any change in its
expectations or any change in events, conditions, or circumstances
on which any such statement is based, except as required by law.
These forward-looking statements should not be relied upon as
representing Cytek’s views as of any date subsequent to the date of
this press release.
Media Contact:Stephanie
OlsenLages & Associates(949) 453-8080stephanie@lages.com
Investor Contact:Paul
GoodsonHead of Investor RelationsCytek
Biosciencespgoodson@cytekbio.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/2051b2e9-9eb7-4d88-b46d-313fc103ffcb
Cytek Biosciences (NASDAQ:CTKB)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Cytek Biosciences (NASDAQ:CTKB)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024